News About: Pharm. Industry
J&J kept Berna Biotech reborn as ‘Janssen Vaccine’
Berna Biotech was reborn as ‘Janssen Vaccine.’
According to the industry concerned on the 20th, a vaccine manufacturer Berna Biotech changed its name to Janssen Vaccine, launched as a subsidiary of a multinational p...
‘Cruel April’ in pharmaceutical industry
The pharmaceutical industry has been messy this April because rebate investigation, FTC’s(Fair Trade Commission) investigation, and tax investigation either was conducted or being conducted now.
First, the pharmaceut...
‘Pfizer Pharmaceuticals Korea’ to spend most advertising expenses in pharmaceutical industry
A company which spend the most advertising expenses last year among other multinational pharmaceutical companies branched in Korea was Pfizer Pharmaceuticals Korea with more than KRW 50 billion. The amount was more th...
Industry pays attention to AZ’s Symbicort Rapihaler
AstraZeneca Korea’s ‘Symbicort Rapihaler’ which strengthened its inhaler portfolio has attracted interests of the industry.
AstraZeneca Korea introduced ‘Symbicort Rapihaler’ through a press conference on the 18th, ...
“Stop distorted rumors,” regarding olmesartan issue
Pharmaceutical companies related to ‘olmesartan’ which is prohibited in health insurance benefit are under a state of emergency.
According to the pharmaceutical industry on the 15th, a number of patients started to r...
Multinational pharmaceutical companies’ average annual wage of KRW 73 million
It was observed the average annual wage of multinational pharmaceutical companies’ employees was KRW 73 million, and employees at GlaxoSmithKline, UCB Korea and Sanofi receive more than KRW 100 million annually.
Acc...
Multinational companies focusing on non-benefit products had high sales management expenses
Last year, multinational pharmaceutical companies were observed to reduce their sales management expenses.
According to the sales management expenses based on 31 multinational companies’ 2015 audit reports on the 15...
Jardiance with KRW 703, Sovaldi with KRW 270,656
18 new products, such as a chronic hepatitis C therapy Sovaldi Tab(sofosbuvir), will be registered for the insurance benefit on the 1st of the next month.
There are 9 products each, products with price negotiated bet...
Multinational company’s annual average sales per employee were KRW 740 million
Annual sales per a person working for a multinational pharmaceutical company branched in Korea were estimated approximately at KRW 740 million.
It was observed Genzyme Korea had the most in the category with KRW 1.48...
Daiichi Sankyo, “Olmesartan’s removal of insurance benefit is not revocation of approval”“The decision is only removal from the insurance benefit, not revocation of approval. We will continue adjusting domestic actions with the Ministry of Food and Drug Safety.”
Wh...
|
